FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology received FDA approval to include dose escalation in the NERLYNX label for both early stage and metastatic breast cancer patients.

Click to view original post